pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

865 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1777Endpoints1386Fierce Biotech704BioSpace695BioPharma Dive524raps234onclive165fda recalls
therapy area
allOncology12301Rare Disease3205Immunology2862Cardiology2727Hematology2177Pulmonology2138Vaccines1794
  • U.S. bioscience jobs up 7% from 2021 to 2025: Report
    Bioscience employment rose in 41 states, though not in California, according to a new report from the Biotechnology Innovation Organization and the Council of State Bioscience Associations.
    BioSpace · 8d agoRegulatoryNeutral↗ source
  • Early Alert: B. Braun Medical Inc. Removes Streamline Bloodline Set for Dialog+
    The dialyzer connector may not be attached appropriately, resulting in leaking and potential blood loss.
    fda medwatch · 8d agoRegulatoryNeutral↗ source
← prev
page 4 of 35
next →
113
fda medwatch111
globenewswire health73
fda press59
Psychiatry & CNS1204
Ophthalmology1051
Pain777
Endocrinology & Metabolism775
Nephrology760
  • FDA warns against Once Upon a Farm Tractor Wheels toddler bars due to choking risk
    The U.S. Food and Drug Administration issued a consumer safety advisory concerning the organic toddler snack Once Upon a Farm Tractor Wheels. The agency cautioned that the soft‑baked bars pose a p…
    fda medwatch · 8d agoRegulatoryNegative↗ source
  • MedWatch Alert: FDA Advises Consumers Not to Buy or Serve Once Upon a Farm Tractor Wheels Organic Toddler Soft-Baked Bars
    Consumers Should Not Buy or Serve Once Upon a Farm Tractor Wheels, Organic Toddler Soft-Baked Bars Due to a Potentially Fatal Choking Hazard
    fda medwatch · 8d ago↗ source
  • FDA grants accelerated approval to first plasmid DNA immunotherapy for adult recurrent respiratory papillomatosis
    The U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) as a treatment for adults with recurrent respiratory pa…
    fda press · 11d agoApprovalPositive↗ source
  • Regeneron posts $5.1 billion Q3 revenue, beating forecasts and highlighting strong sales of Dupixent, Eylea HD and Libtayo
    Regeneron reported third‑quarter revenue of $5.1 billion, well above the consensus range of $4.61‑$4.65 billion and representing a 36% increase from the same period last year. The company attribut…
    BioSpace · 11d agoEarningsPositive↗ source
  • AbbVie beats Q3 expectations, lifts full-year EPS outlook as immunology and neuroscience drive growth
    AbbVie reported third-quarter results that exceeded analysts' sales and earnings per share forecasts. The company posted $17.4 billion in revenue, driven largely by its immunology franchise which…
    BioSpace · 11d agoEarningsPositive↗ source
  • Alnylam shares tumble 25% as analysts flag uncertainties in its transthyretin franchise
    Alnylam Therapeutics saw its stock fall about a quarter on Thursday, closing near $174 after analysts highlighted a trio of uncertainties surrounding its transthyretin (TTR) franchise. The TTR fra…
    BioSpace · 11d agoEarningsNegative↗ source
  • Early-stage data show promise for targeting Wnt/β-catenin pathway across cancers
    Early-stage clinical results from the company and several peers indicate that the Wnt/β-catenin signaling pathway could become a viable target for treating a range of tumor types. The pathway has…
    BioSpace · 11d agoPositive readoutPositive↗ source
  • Instrumentation Laboratories recalls several lots of HemosIL AcuStar HIT-IgG(PF4-H) assay due to false-negative risk
    Instrumentation Laboratories (Werfen) has issued a recall of specific lots of its HemosIL AcuStar HIT-IgG(PF4-H) radioimmunoassay after the FDA identified a performance issue that could produce fal…
    fda medwatch · 11d agoCRLNegative↗ source
  • AstraZeneca launches $1.5 billion cost-saving plan to fund growth, says no layoffs expected
    AstraZeneca announced a three-year cost‑saving initiative worth $1.5 billion during its third‑quarter earnings call. The program, called Reshaping for Sustainable Growth, aims to redeploy resource…
    BioSpace · 11d agoEarningsPositive↗ source
  • Sanofi eyes late-stage and commercial acquisitions to counter upcoming Dupixent revenue drop
    Sanofi said on its third‑quarter earnings call that it is looking to acquire late‑stage and commercial medicines to sustain growth after Dupixent loses exclusivity. CEO Belén Garijo highlighted th…
    BioSpace · 11d agoDealPositive↗ source
  • Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programs
    Setara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…
    BioSpace · 11d agoDealPositive↗ source
  • Nova Biomedical issues safety instructions for StatStrip Glucose Hospital Meter Gen 2.0
    Nova Biomedical has sent a letter to customers using the StatStrip Glucose Hospital Meter System Gen 2.0, advising updated use instructions while a software fix is prepared. The FDA classified the…
    fda medwatch · 11d agoCRLNegative↗ source
  • Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
    Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.
    BioSpace · 11d agoRegulatoryNeutral↗ source
  • Merck projects continued investment and growth as Keytruda patent expires
    Merck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
    BioSpace · 12d agoEarningsPositive↗ source
  • Eli Lilly lifts guidance by $10 billion as GLP‑1 sales outpace expectations
    Eli Lilly said its latest financial guidance is $10 billion higher than previously forecast, driven by strong sales of its GLP‑1 medicines. The company’s commercial performance has repeatedly excee…
    BioSpace · 12d agoEarningsPositive↗ source
  • Dren Bio raises $350 million to advance rare blood cancer antibody
    Dren Bio, a California biotech, announced a $350 million financing round to fund late‑stage development and commercial preparation of its lead therapy, a CD94‑targeting monoclonal antibody known as…
    BioSpace · 12d agoDealPositive↗ source
  • Biopharma manufacturing cuts slated to affect over 4,000 workers, with BioNTech leading layoffs
    Companies investing billions to reshore drug production are trimming staff at manufacturing sites, with ten biotech and pharma firms planning cuts that could affect more than 4,000 employees. BioN…
    BioSpace · 12d agoLayoffsNegative↗ source
  • Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studies
    Ono Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…
    BioSpace · 12d agoNegative readoutNegative↗ source
  • Australia emerges as a hub for early-stage clinical trials thanks to speed, clear regulations and tax incentives
    A recent episode of BioSpace’s Denatured podcast featured Jerome Barley of Avion Medical and Ryan Klein of Resolian discussing Australia’s growing appeal for early-stage clinical development. The…
    BioSpace · 12d agoPositive↗ source
  • BMS shelves Prothena-partnered neuro drug after Phase 1 review, but raises full-year revenue outlook on 7% Q3 sales growth
    Bristol Myers Squibb announced it will not move forward with the neurodegeneration candidate BMS-986495 (PRX019), a monoclonal antibody licensed from Prothena. The decision follows a review of Phas…
    BioSpace · 12d agoNeutral↗ source
  • Medline orders removal of all brand beds and accessories over fire and asphyxiation hazards
    Medline has issued an urgent field safety notice indicating that all of its branded hospital beds and related components must be removed or corrected because of identified safety risks. The FDA’s…
    fda medwatch · 12d agoRegulatoryNegative↗ source
  • Biopharma job postings in New York surge 109% year over year, eight firms hiring
    BioSpace data shows that biopharma job postings in New York have surged, rising 109% from Oct 1 2025 to Oct 26 2026, with month‑over‑month gains of 32% in August‑September and 19% in September‑Octo…
    BioSpace · 12d agoPositive↗ source
  • Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
    Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
    BioSpace · 12d agoEarningsNeutral↗ source